INTRODUCTION
Low back pain (LBP) is a considerable source of morbidity worldwide; a systematic review reported that approximately 12% of the general population is affected. 1 The 2010 Global Burden of Disease study, which measured the disability burden associated with nearly 300 diseases and injuries (including cancer, cardiovascular diseases, injuries, communicable and noncommunicable diseases, nutritional disorders, musculoskeletal disorders, maternal/neonatal disorders, and mental health conditions 2 ), ranked LBP as the highest worldwide in terms of disability and sixth in terms of overall burden of disease. 3 LBP is chronic or relapsing for at least 5% to 10% of sufferers, and is severe for approximately 11%. 4 There are many causes for LBP, and detailed assessments are generally required before the pain can be attributed to a specific pathology. 5 In the case of failed back surgery syndrome (FBSS), previous surgical procedures can contribute to LBP.
Spinal cord stimulation (SCS) can be an effective treatment for LBP under certain circumstances. In one of the first prospective investigations specific to SCS for LBP, 4-contact cylindrical leads placed on the midline at approximately T9-T10 could achieve paresthesias in the low back for about two thirds of patients at 12 months postimplantation, with an average LBP pain relief of 46% at an average postimplantation follow-up of 2.3 years. 6 Similarly, a study using hybrid percutaneous paddle leads at the T7-T9 levels yielded an average of 44% LBP relief, with 51% of subjects reporting better than 50% pain relief at 12 months. 7 A recent trial investigating an algorithmic approach to tricolumn paddle lead programming revealed that paresthesia concordance of painful areas in the low back could be achieved with at least 1 programming combination for 85.7% of subjects at 6 months postimplantation, with an average of 80% pain relief in the low back. 8 However, the evidence for SCS as an LBP treatment across the literature is inconsistent, 9 and the radicular leg pain component appears to be more amenable to treatment with SCS than LBP. 10 This has been consistently demonstrated across multiple reports, 7, 11, 12 including a controlled trial of subjects with predominant back pain complaints. 13 In addition to conventional tonic programming, the preferential benefit for leg pain over LBP has been observed with burst and highfrequency tonic patterns of stimulation. 14, 15 Other challenges to treat LBP include difficulty in precise lead placements along the physiological midline and difficulty achieving effective programming while avoiding side effects. 6, 8 Additionally, a considerable portion of sensory fibers projecting from the low back are located deep in the axial dorsal columns, a site that is difficult to recruit with SCS. 16 Preclinical studies in animal models have shown that the rami communicantes carry afferents from the discs and facet joints. [17] [18] [19] This nonsegmental neural pathway between intrinsic pain-generating structures in the low back and their L1-L3 dorsal root ganglia (DRGs) is not straightforward, as the white ramus communicans nerve does not continue caudal to the L2 level. 20 A tracttracing study in rats showed that the L5-L6 disc is innervated by the T13-L6 DRGs through segmental pathways, and by the L13-L2 DRGs through sympathetic trunks. 21 In humans, the L1 and L2 DRG have the highest proportion of nonsegmental peripheral innervation that is carried via the sympathetic trunk. 18 Thus, in humans, pain signals arising from intravertebral discs may project rostrally through the sympathetic trunk and converge at the L2 DRG via the caudalmost white ramus communicans nerve.
Pain management procedures involving L2-L3 nerve roots and DRG are effective for LBP. For example, nerve blocks at the L2 level relieved LBP (in contrast to the limited relief of radicular pain and sciatica), while L2 provocation induced pain that radiated to the low back. 22 In a randomized study design, L2 blocks were more effective than placebo for LBP and radicular pain. 23 Similarly, pulsed radiofrequency (RF) of the L2 DRG was effective for LBP, 24 as was RF lesioning of the ramus communicans nerve of L2. 25 Such procedures, however, provide only temporary pain relief and may therefore be less preferable than neuromodulatory interventions that can potentially provide reliable, long-term pain relief for LBP. DRG stimulation recently emerged as an attractive option in neuromodulation pain management. These novel neural targets are positioned at each segmental level of the spinal column and contain the cell bodies of somatic and autonomic afferents as they travel from the periphery and enter the spinal cord. Preliminary evidence suggests that stimulation of L2-L3 DRGs may be an effective treatment for LBP, 26, 27 and the objective of this report is to further investigate these observations.
METHODS
A prospective clinical trial for the treatment of chronic pain with DRG stimulation was conducted across 2 investigative sites in the European Union with the oversight of local ethics committees and with subjects' written informed consent. A subset of the subjects in that study was retrospectively identified and analyzed for the present report. Standard data management quality procedures were followed according to Good Clinical Practice. Included were all consecutive subjects who had back pain due to FBSS, reported axial LBP as either their primary or secondary region of pain with an overall baseline visual analog scale (VAS) score of 60 mm or more, had a successful DRG stimulation trial with better than 50% pain relief, and had at least 1 lead permanently implanted at an L2 or L3 DRG.
Subjects underwent implantation of DRG stimulation systems (Abbott Laboratories, Abbott Park, IL, U.S.A.); methods have been described previously. 28, 29 Up to 4 leads were implanted per subject and were placed at the DRG corresponding to the subject's individual pain distribution and based on empirical intraoperative feedback of paresthesia locations. Specifically, the levels at which leads were implanted corresponded to the dermatomal location of each subject's primary region of pain. During intraoperative testing, additional leads were placed in order to provide optimal stimulation coverage in the areas of pain being treated.
Prospective data collection was completed postimplantation at the 1-week, 1-month, 3-month, 6-month, and 12-month follow-ups. Outcome ). Severe adverse events (SAEs) and adverse events (AEs) were collected throughout the study period at each follow-up.
Twelve-month outcomes were statistically compared to baseline using paired t-tests with a type I error rate of 0.05. Unless otherwise stated, data are presented at means AE standard error of the mean (SEM).
RESULTS
Twelve subjects meeting the subset criteria were included; their average age was 51.1 years, and 33% of the group was male. The average overall pain at baseline averaged 77.6 mm (AE2.0). All subjects suffered from FBSS with pain; LBP was the primary or secondary region of pain for all subjects, with the intensity of pain in the low back rated as 73.9 mm (AE3.7) at baseline. All subjects also had leg pain (69.6 AE 4.8 mm), albeit of lower average intensity than that of the low back. Additionally, 6 subjects also had foot pain and 2 subjects had buttock pain (Tables 1 and 2) .
Among the 12 subjects, a total of 29 leads were implanted in the lumbar spine (Table 3 ). All subjects had at least 1 lead at L2 or L3; 11 subjects (92%) had a total of 17 leads (58.6%) at L2, while 9 subjects (75%) had a total of 9 leads (31.0%) at L3.
Additionally, 1 lead was placed at each of the L1, L4, and S1 DRG in subjects with foot and buttock pain in order to establish adequate paresthesia concordance with all painful areas. Leads were typically programmed in a bipolar configuration. The average stimulation settings for leads implanted at L1, L2, and L3 were as follows: pulse width, 269 ls (AE17.0, range 80 to 440); frequency, 21.3 Hz (AE0.6, range 20 to 30); and amplitude, 591.9 lA (AE50.3, range 1,750 to 1,130).
Pain ratings in the low back were reduced by 50.8% at 6 months (to 37.5 AE 9.4 mm) and by 45.5% at 12 months (to 40.4 AE 9.7 mm; P < 0.001) (Figure 1) . The proportion of subjects with at least 50% pain relief in the low back was 58.3% at 12 months, and these responders reported LBP relief of 76.9% (Figure 2 ). The proportion of nonresponder subjects (41.7%) who reported less than 50% pain relief at 12 months experienced LBP reduction of 3.7% (see Figure 2) . Similarly, overall pain ratings were reduced by 38.2% at 6 months (to 49.2 AE 9.6 mm) and by 44.2% at 12 months (to 44.6 AE 9.5 mm; P < 0.001). Leg pain was reduced by 47.6% at 6 months (from 69.6 AE 4.8 mm at baseline to 35.1 AE 8.3) and by 60.8% at 12 months (to 25.8 AE 9.3 mm; P < 0.001) (see Figure 1) . When subjects were asked, "Do you have pain relief in the areas where you usually have pain?", 100% of subjects responded affirmatively at the end of the trial period, and the majority of subjects continued to responded affirmatively through 12 months ( Figure 3 ). Pain severity as rated by the BPI was reduced from 6.9 AE 0.4 to 5.6 AE 0.7 at 12 months. Similarly, BPI pain interference decreased from 5.6 AE 0.5 to 3.6 AE 0.7. Subjects also reported sustained improvements in mood, as the POMS total mood disturbance rating decreased from 22.3 AE 5.9 at baseline to 14.1 AE 5.3 at 12 months. Quality of life, as expressed by EQ-5D index ratings, increased from 0.313 AE 0.07 at baseline to 0.495 AE 0.08 at 12 months. All differences were statistically significant (P < 0.05); repeated measures throughout the follow-up time period are presented in Table 4 .
Over the course of the study, a total of 4 SAEs (33.3% rate), 2 AEs (16.7% rate), and 4 lead revisions (25.0% rate) were recorded among 12 subjects. Of the 4 SAEs, 3 were categorized as moderate, 1 was categorized a severe, and all were categorized as not related to the study devices. These events included temporary loss of leg strength following the procedure, post-dural puncture headache, bladder infection, and depression. A total of 2 AEs were recorded, but were reported from a single subject. The first mild AE was discomfort at the implantation site that was categorized as probably related to the study device. This event was resolved by a revision of the implantable pulse generator placement. The second mild AE was wound infection resulting from the revision procedure, which was successfully treated with antibiotics. Of the 4 successful lead revisions performed; 2 addressed the loss of pain relief and 2 shifted the stimulation to the correct area of pain.
DISCUSSION
Dorsal root ganglion stimulation has been recently developed as an alternative to SCS and has been used effectively as a treatment for chronic neuropathic pain of various etiologies in the trunk and limbs. [35] [36] [37] [38] The current data suggest that DRG stimulation at the L2-L3 levels also induces pain relief in the low back, as well as in overall pain. There was significant pain relief in the low back: more than 50% of patients reported greater than 50% pain relief at 6 and 12 months (58.3% and 54.5%, respectively). These outcomes are superior to those of the PROCESS study, a randomized controlled trial with intent-to-treat analysis methods that compared conventional medical management (CMM) with SCS combined with CMM. PROCESS subjects treated with SCS plus CMM had baseline back pain ratings of approximately 56 mm that were reduced to 45 mm at 12 months (a 20% reduction). Furthermore, the back pain results in the current report are comparable to those of a recent meta-analysis demonstrating that the relief afforded by SCS is approximately 58%. However, only 3 of the 63 studies included in the meta-analysis had back-specific outcomes (the remainder reported outcomes for leg pain or some combination of back and leg pain 10 ). LBP relief with DRG stimulation was durable through 12 months of follow-up. As is common in FBSS patients, subjects in this report experienced concomitant leg pain, and in some cases, foot and buttock pain, in addition to their predominant back pain. With the exception of the buttock pain in 2 subjects, DRG stimulation was simultaneously effective at relieving pain in those regions. In addition to the pain outcomes outlined above, the subjects in this report experienced improvements in their pain-related interference with daily function, mood, and quality of life during the year of treatment. Daily function, as rated by the Interference scale of the BPI, 39 improved by 35.7% over the course of the year. The POMS total mood disturbance rating, a combination of tension, depression, anger, fatigue, confusion, and vigor domains, was clinically elevated at baseline but declined to normal ranges after a year of treatment. 40 Health- Representative maps of baseline pain (left column) and paresthesia (right column) from three subjects (A, B, and C). These paresthesias were generated using programming parameters that the subjects were using as their typical at-home settings. All of these subjects had more than 80% pain relief specific to the low back. Paresthesias could be perceived in the low back (subjects A and B), but perceptible paresthesias were not a requirement for back pain relief (subject C). related quality of life on the EQ-5D also improved. These converging outcomes suggest that DRG stimulation achieves the multimodal goals of a pain management intervention for LBP. This cohort of FBSS patients reported experiencing pain relief in the regions that usually had pain, which in this case involved predominantly the low back. This suggests that the pain-paresthesia coverage concordance was adequate. In alignment with the literature showing that nerve blocks and RF lesioning at the L1-L3 nerve roots and DRG is effective treatment for LBP, [23] [24] [25] this report provides additional evidence that DRG stimulation at these upper lumbar levels is an effective intervention for pain in the lower lumbar region. There are several anatomical reasons that may explain this phenomenon. The dorsal aspects of the lower lumbar (L4-L5) spine are known to be a source of LBP; these include the intervertebral discs, 41 sacroiliac joint, 42 Figure 4. Afferents carrying pain signals from intrinsic lumbar spinal structures such as intravertebral discs enter the sympathetic trunk and traverse rostrally. They then converge to be carried through the caudal-most white ramus communicans nerve at L2, pass near/ through the L2 DRG, and into the spinal cord. lumbar facet joints, 17 ,43 dura mater, 44 and lumbar vertebrae themselves. 45 These areas are innervated by sensory afferents that project through somatic spinal nerves, as well as by sympathetic nerves, both of which converge in the L2-L3 DRG (Figure 4) . DRG stimulation at L2-L3 may be effective for patients with intractable discogenic LBP by modulating these segmental and nonsegmental neural pathways that are not otherwise accessible with traditional SCS.
For those subjects who reported less than 50% reduction in LBP at the 12-month follow-up (41.7%), there are multiple possible explanations. While the focus of this study is on subjects with a primary diagnosis of FBSS, it is important to differentiate iatrogenic pain resulting from a previous surgical procedure and pain originating from pre-existing conditions and/or issues that develop once treatment is complete. 46 There are many causes for LBP, and detailed assessments are generally required before the pain can be attributed to a specific pathology. 5 Studies using diagnostic nerve blocks have reported that pathology of the spinal disc, facet joint, and sacroiliac joint are the sources of pain in the majority of cases. 47, 48 With the current data set, it is not possible to identify and separate the origins of these painful symptoms. It is also possible that a surgical procedure in the low back may itself generate new sources of pain. Additional studies are warranted to investigate these potentially independent sources of pain and whether they respond differently to stimulation of the DRG. This study is limited by its small sample size; even so, the study inclusion criteria ensured that the subjects were representative of the population, and the statistical power was high. Future prospective studies, with larger sample sizes, should further evaluate DRG stimulation at the L2-L3 DRG in the treatment of FBSS. Finally, as DRG stimulation is both more invasive and expensive compared to other conventional treatment options, a risk-benefit analysis is important when evaluating this treatment option. As such, additional prospective studies are warranted to further investigate this application of DRG stimulation, as well as to optimize patient selection and position in the FBSS treatment algorithm.
CONCLUSIONS
In this report, subjects with LBP due to FBSS were treated with DRG stimulation at L2-L3. Pain was significantly relieved and improvements in function, mood, and quality of life were achieved and sustained at 12-month follow-up. Long-term positive health outcomes such as these have been elusive using temporary nerve blocks at L2-L3 or traditional SCS. Stimulation at the L2-L3 DRG may uniquely engage segmental and nonsegmental mechanisms of action through primary sensory afferents and sympathetic pathways, respectively, projecting from the lower lumbar regions. Further controlled investigations are warranted to further characterize the pathogenesis of LBP and to prospectively study the clinical outcomes of this novel DRG stimulation treatment.
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